French metabolic disorders company Poxel SA and Asia partner Sumitomo Dainippon Pharma Co. Ltd. (SDP) say they remain on track for a planned Japanese approval submission sometime in 2020 for imeglimin, following new top-line Phase III results for the novel antidiabetic.
The plan could potentially lead to a 2021 launch for the oral glimin class molecule in what may become the first market worldwide for the Merck Serono spin-out's lead asset.